TRYVIO (aprocitentan)

Self-Administration-oral tablets

Diagnosis considered for coverage:

Hypertension: Indicated in combination with other antihypertensive drugs, for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs.

Coverage Criteria:

For diagnosis of resistant hypertension:

  • Diagnosis of hypertension; AND

  • Patient has not achieved target blood pressure (e.g., systolic blood pressure [SBP] less than 130 mmHg) after treatment with ALL of the following antihypertensive medications from different classes for an adequate duration (minimum 4 weeks each) at a maximally tolerated dose: 

    • One of the following: 

      • Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril) 

      • Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan) 

    • Diuretic (e.g., hydrochlorothiazide, chlorthalidone) 

    • Calcium channel blocker (e.g., amlodipine, nifedipine) 

    • Mineralocorticoid receptor antagonist (MRA) [e.g., eplerenone, spironolactone]; AND 

  • Provider attests other causes of hypertension have been excluded (e.g., secondary causes, white coat effect, medication nonadherence); AND 

  • Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program); AND

  • Requested drug will be used in combination with at least 3 antihypertensive medications from different classes; AND

  • Prescribed by or in consultation with a specialist experienced in the treatment of resistant hypertension (e.g., cardiologist, nephrologist) 

Reauthorization Criteria:

For diagnosis of resistant hypertension:

  • Patient demonstrates positive clinical response to therapy (e.g., systolic blood pressure [SBP] less than 130 mmHg); AND

  • Patient continues to use Tryvio in combination with at least 3 antihypertensive medications from different classes and is adherent to therapy; AND

  • Requested drug will continue to be used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program); AND

  • Patient has been previously treated with ALL of the following antihypertensive medications from different classes for an adequate duration (minimum 4 weeks each) at a maximally tolerated dose: 

    • One of the following: 

      • Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril) 

      • Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan) 

    • Diuretic (e.g., hydrochlorothiazide, chlorthalidone) 

    • Calcium channel blocker (e.g., amlodipine, nifedipine) 

    • Mineralocorticoid receptor antagonist (MRA) [e.g., eplerenone, spironolactone] 

Coverage Duration:
  • Initial: 6 months

  • Reauthorization: 1 year

Dosing:

For diagnosis of resistant hypertension:

  • The recommended dosage of TRYVIO is 12.5 mg orally once daily, with or without food.

Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Tryvio is the first endothelin receptor antagonist (ERA) approved for the treatment of hypertension.

  • ERAs cause hepatotoxicity and liver failure. Measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and repeat periodically during treatment and as clinically indicated.

  • No head-to-head data are available Tryvio vs other antihypertensives in resistant hypertension, including spironolactone, which is currently recommended as a preferred add-on therapy.

Policy Updates:
  • 12/01/2024 – New policy for Tryvio approved by WHA P&T Committee. (P&T, 11/21/2024)

References:
  1. Tryvio Prescribing Information. Idorsia Pharmaceuticals US Inc. Radnor, PA. April 2024. 
  2. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5). 
     

Last review date: December 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone